Bank of New York Mellon Corp Trims Stake in Diversified Healthcare Trust (NASDAQ:DHC)

Bank of New York Mellon Corp trimmed its stake in Diversified Healthcare Trust (NASDAQ:DHC) by 21.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 763,275 shares of the real estate investment trust’s stock after selling 203,794 shares during the period. Bank of New York Mellon Corp owned 0.32% of Diversified Healthcare Trust worth $1,756,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. ING Groep NV purchased a new position in shares of Diversified Healthcare Trust during the fourth quarter valued at about $460,000. Inspire Investing LLC lifted its holdings in shares of Diversified Healthcare Trust by 78.7% in the 4th quarter. Inspire Investing LLC now owns 175,182 shares of the real estate investment trust’s stock valued at $403,000 after acquiring an additional 77,170 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Diversified Healthcare Trust by 55.1% in the 4th quarter. SG Americas Securities LLC now owns 116,782 shares of the real estate investment trust’s stock valued at $269,000 after acquiring an additional 41,489 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Diversified Healthcare Trust by 60.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 863,806 shares of the real estate investment trust’s stock valued at $3,619,000 after acquiring an additional 324,787 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of Diversified Healthcare Trust by 310.2% in the 3rd quarter. Barclays PLC now owns 324,514 shares of the real estate investment trust’s stock valued at $1,360,000 after acquiring an additional 245,405 shares during the last quarter. Hedge funds and other institutional investors own 75.98% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of Diversified Healthcare Trust from a “hold” rating to a “sell” rating in a research note on Wednesday, February 26th.

Diversified Healthcare Trust Price Performance

NASDAQ DHC opened at $2.45 on Friday. The firm’s fifty day simple moving average is $2.50 and its two-hundred day simple moving average is $2.83. The company has a current ratio of 11.57, a quick ratio of 11.57 and a debt-to-equity ratio of 1.44. Diversified Healthcare Trust has a 12-month low of $2.01 and a 12-month high of $4.24. The firm has a market capitalization of $591.12 million, a P/E ratio of -1.52 and a beta of 2.15.

Diversified Healthcare Trust (NASDAQ:DHC) last posted its quarterly earnings data on Tuesday, February 25th. The real estate investment trust reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.31. Diversified Healthcare Trust had a negative net margin of 26.09% and a negative return on equity of 17.55%. The business had revenue of $379.62 million during the quarter, compared to the consensus estimate of $370.97 million.

Diversified Healthcare Trust Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 20th. Stockholders of record on Monday, January 27th were paid a dividend of $0.01 per share. The ex-dividend date of this dividend was Monday, January 27th. This represents a $0.04 annualized dividend and a dividend yield of 1.63%. Diversified Healthcare Trust’s payout ratio is currently -2.60%.

Diversified Healthcare Trust Company Profile

Diversified Healthcare Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Office Portfolio, Senior Housing Operating Portfolio (SHOP), and Non-Segment. The Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants.